Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules Academic Article Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Urinary Bladder Neoplasms

abstract

  • ITP is an active, well-tolerated regimen for previously untreated patients with TCC of the urothelial tract, resulting in a median survival of 20 months. Treatment can be recycled at 3-week intervals without enhanced toxicity.

publication date

  • April 2000

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1097-0142(20000401)88:7<1671::AID-CNCR22>3.0.CO;2-A

PubMed ID

  • 10738226

Additional Document Info

start page

  • 1671

end page

  • 8

volume

  • 88

number

  • 7